CMN Weekly (14 October 2022) - Your Weekly CRISPR Medicine News
Some of the best links we picked up around the internet
By: Gorm Palmgren - Oct. 14, 2022
American researchers have used cross-species evolution to engineer a highly potent AAV variant for therapeutic gene transfer and genome editing. The variant, AAV.cc47, shows improved attributes benchmarked against AAV serotype 9 as evidenced by robust reporter and therapeutic gene expression, Cre recombination and CRISPR genome editing in normal and diseased mouse models. Furthermore, AAV.cc47 vectors are also efficient in macaques and pigs, suggesting that they might improve predictive modelling in preclinical studies and clinical translatability by broadening the therapeutic window of AAV-based gene therapies.
A new sensitive detection system for evaluating the DNA methylation level can contribute to the prognosis and diagnosis of cancer, suggest Chinese researchers. The novel assay is based on endonuclease-assisted protospacer adjacent motif (PAM)-free recombinase polymerase amplification coupling with CRISPR-Cas12a after digestion of unmethylated DNA with the methylation-sensitive restriction enzyme.
Researchers in Saudi Arabia discuss cancer management strategies in a review that aims to provide in-depth updates on Streptococcus pyogenic CRISPR-Cas9 structure and its mechanistic understanding. In addition, the advances in its nanoformulation-based delivery systems, including lipid-based, polymeric structures and rigid NPs coupled to particular ligands such as aptamers, TAT peptides and cell-penetrating peptides, are discussed.